NFL Biosciences shares rose on Friday morning following the announcement that businessman Gérard Leduc, a well-known entrepreneur in the pharmaceutical sector, had acquired a stake in GB Holding.

Shares in the biopharmaceutical company, which develops botanical medicines for the treatment of dependencies and addictions, are currently up by almost 3%, while the Paris market is up by around 0.7%.

GB Holding exercised 100.000 share subscription warrants (BSA), bringing its stake in NFL Biosciences to around 11.2%, a level the businessman has undertaken to maintain for at least nine months.

NFL recalls that Gérard Leduc notably founded, managed and sold Ethypharm, a European pharmaceutical laboratory specializing in central nervous system (CNS) pathologies and hospital injectables, which had over 800 employees.

'Products to treat addictions have always been of great interest to me', he explained. NFL-101, for smoking cessation, is a potentially revolutionary product with a completely new mechanism of action", added the entrepreneur.

This equity investment comes at a time when the first results of the two clinical studies on NFL-101 for smoking cessation are expected in the 3rd and 4th quarters of 2023.

Copyright (c) 2023 CercleFinance.com. All rights reserved.